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Abstract 26 
Macrophages are found throughout the body, where they play crucial roles in tissue 27 
development, homeostasis and remodelling, as well as being sentinels of the innate immune 28 
system that can contribute to protective immunity and inflammation. Barrier tissues such as 29 
the intestine, lung, skin and liver are exposed constantly to the outside world, placing 30 
special demands on resident cell populations such as macrophages. Here we review the 31 
mounting evidence that although macrophages in different barrier tissues may be derived 32 
from distinct progenitors, their highly specific properties are shaped by the local 33 
environment, allowing them to adapt precisely to the needs of their anatomical niche. We 34 
discuss the properties of macrophages in steady state barrier tissues, outline the factors 35 
that shape their differentiation and behaviour and describe how macrophages change 36 
during protective immunity and inflammation. 37 
 38 
1. Introduction 39 
Macrophages (mφs) are one of the most abundant populations of leukocytes in the 40 
body. They play important roles in innate immunity and inflammation1, but are also crucial 41 
for the development and homeostatic maintenance of normal tissues, as well as in the 42 
repair of damaged tissue2. Hence, there is considerable interest in exploring how mφs are 43 
tailored to the physiological demands of their environment and how this changes when 44 
homeostasis is perturbed.  45 
 Until very recently, it was believed that mφ behaviour could be explained by dividing 46 
them into discrete subsets (“M1-like” and “M2-like”) based on their functional properties. 47 
However work over the past few years shows that this approach is over-simplistic3 and that 48 
mφs are highly heterogeneous, possessing specialised properties that are precisely adapted 49 
to individual tissues. In parallel it is now clear that local factors in the environment control 50 
how mφs develop and function under both steady state and inflammatory conditions. Here 51 
we discuss how this new understanding of macrophage biology provides insights into the 52 
behaviour of these cells in the most immunologically active tissues in the body, the barrier 53 
surfaces of the skin, intestine, lung and liver. As these sites are exposed continuously to the 54 
external environment and are of crucial physiological importance, they require constant 55 
monitoring for pathogens, but also maintenance of tissue integrity. As a result, immune cells 56 
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in the barrier surfaces are subject to unique demands and the macrophage populations 57 
have many unusual properties. 58 
 59 
2. Macrophages in Steady State Tissues 60 
Mφs are sessile mononuclear cells found in all tissues of the body, where they have 61 
the appearance of large vacuolated cells with abundant cytoplasm containing lysosomal 62 
granules. Classically, tissue mφs have been identified on the basis of F4/80 and CD68 63 
expression in mice and humans respectively, but recent multi-parameter flow cytometric 64 
analyses and genome-wide transcriptional profiling have revealed additional generic 65 
markers that identify mφs across a range of tissues4 (Table 1). Of particular note and of 66 
practical importance, the high affinity IgG receptor CD64 and Mer tyrosine kinase (MerTK) 67 
are common to most tissue mφs in mice and are not expressed highly by other mononuclear 68 
phagocytes (MPs), such as dendritic cells (DCs)5.  69 
Layered on top of this common signature, mφs in individual tissues are remarkably 70 
heterogeneous in terms of their surface phenotype, transcriptome and epigenome (Table 1 71 
and see below). Although many of their functions are conserved across tissues, including 72 
key housekeeping functions such as clearance of apoptotic and senescent cells, individual 73 
populations of mφs are highly adapted to the needs of their environment, fulfilling roles 74 
specific to the particular tissue, and even subcompartments within tissues6. This 75 
heterogeneity is not surprising given the significant differences between organs in terms of 76 
their physiological functions, exposure to microbiota, nutrients and metabolites, and the 77 
fact that mφs develop synchronously with their organ of residence7. For a time, it was 78 
believed that these differences might reflect distinct developmental origins of mφs, but it 79 
now seems more likely that local environmental imprinting is the major determinant in mφ 80 
identity and function, irrespective of their origin8. As these general topics have recently 81 
been reviewed extensively (eg see 7-12), here we restrict our discussion of those aspects of 82 
mφ origin and development that are specific to the barrier surfaces.  83 
 84 
A) Intestinal macrophages.  85 
i) Mucosal Macrophages: Mφs are abundant in all layers of the normal small and large 86 
intestines, including the lamina propria (LP) of the mucosa, the muscularis externa and the 87 
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serosa that separates the intestine from the peritoneal cavity. The largest population is in 88 
the LP, where they are often found immediately below the single layer of columnar 89 
epithelium. In mice, mature mφs of the LP express high levels of MHCII, and most express 90 
CD11c to some extent, often resulting in their confusion with DCs13 14-17 (Table 1). They are 91 
also rich in receptors associated with phagocytic activity and uptake of apoptotic cells, such 92 
as CD163, CD206, TIM4, αvβ5 integrin and CD3614,18-21. Importantly, human intestinal mφs 93 
share many of these features14,22 (Table 1). 94 
 Unlike many other tissue resident mφs, those in the adult intestine are dependent on 95 
constant replenishment by bone marrow derived monocytes which then differentiate locally 96 
under control of factors in the environment including TGFβ20,23-25 (Figure 1A). This 97 
continuous process allows flexible adaptation to the rapidly changing niche represented by 98 
the mucosa. During their differentiation, mucosal mφs progressively acquire their 99 
characteristic phenotype, together with a number of functions that contribute to 100 
homeostasis in the steady state intestine (Figure 1A). They have avid phagocytic activity and 101 
are bactericidal without exogenous stimulation and together with their subepithelial 102 
location, they are ideally situated to deal with pathogenic microbes that invade across the 103 
intestinal epithelium, as well as contribute to the symbiotic relationship with the 104 
microbiota19,25-27. Local mφs can also help preserve integrity of the mucosa in a number of 105 
ways. First their scavenger properties will enable them to deal with the large amount of cell 106 
death that occurs routinely in this highly dynamic tissue. Secondly they secrete mediators 107 
that drive epithelial cell renewal, including hepatocyte growth factor (HGF)28, members of 108 
the Wnt signalling pathway29-31 and PGE232. Finally they produce metalloproteinases that 109 
may promote tissue remodelling20. As a result, loss of mucosal mφs in mice leads to 110 
dysregulated enterocyte differentiation and increased susceptibility to inflammatory 111 
damage(33,34 and see below). 112 
A prominent feature of steady state intestinal mφs is their constitutive production of 113 
IL1014,21,35,36, together with some TNFα and IL1β14,37,38. Despite this, they fail to produce 114 
pro-inflammatory cytokines, nitric oxide or reactive oxygen species (ROS) when stimulated 115 
by agents such as TLR ligands14. This does not reflect a failure to express appropriate 116 
pattern recognition receptors (PRR), but rather may be due to active inhibitory mechanisms 117 
that block the relevant signalling pathways22,39,40. Signalling via the IL10 receptor plays a 118 
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crucial role in the functional “anergy” of intestinal mφs, with defects in this pathway leading 119 
to mφ hyperactivity and inflammatory bowel disease21,41-43. IL10 produced by mφ 120 
themselves is not essential for this process and additional sources of this cytokine in the 121 
mucosa, such as CD4+ T cells, seem to be more important21.  122 
Intestinal mφs are also important sources of mediators that help maintain other immune 123 
cells in their vicinity. Mφ-derived IL10 sustains the expansion and survival of inducible 124 
FoxP3+ Treg in the LP35,44, a process that is important for tolerance to orally administered 125 
antigens44. In parallel, the numbers of endogenous FoxP3+ T cells in different segments of 126 
the intestine correlate with mφ numbers45. IL1β produced by mucosal mφs may play a 127 
similar role in promoting the survival of local IL17 producing CD4+ T cells37 and in driving 128 
secretion of CSF2 from type 3 innate lymphoid cells (ILC3)38. Mature intestinal mφs also 129 
produce a number of chemokines that can recruit T cells and other immune cells, including 130 
their own monocyte precursors17,20 (Figure 1A).  131 
The high expression of MHCII by steady state intestinal mφs raises questions of whether 132 
they can behave as antigen presenting cells (APCs) in vivo. However mφs are sessile in the 133 
mucosa and do not migrate to the draining mesenteric lymph node (MLN)13. Therefore, they 134 
are unlikely to be important for priming naïve T cells, which are found only in secondary 135 
lymphoid organs and not the mucosa. Whether mφs might present antigen to T cells after 136 
their arrival in the mucosa remains to be resolved. Mφs may also cooperate with mucosal 137 
DCs during the induction of local immune responses through antigen transfer to migratory 138 
DCs46,47. Additionally, human intestinal mφs are capable of producing retinoic acid by 139 
metabolism of dietary vitamin A, a property that is restricted to intestinal DCs in mice and 140 
which could suggest that mφ might assist the imprinting of gut homing in human T cells48,49. 141 
 142 
ii) Specialised macrophage microenvironments within the intestine? 143 
Much of what we know about intestinal mφs comes from studies using cells isolated 144 
from the LP of whole tissue or biopsies. Thus there is limited information on how mφs might 145 
behave in the different anatomical compartments within the mucosa. There are relatively 146 
more mφs in the LP of the colon than the small intestine50, possibly reflecting differences in 147 
the functions and bacterial loads in these tissues.  148 
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Mφs are found in a number of locations within the mucosa itself, ranging from 149 
immediately next to the basement membrane underlying the epithelium to the central core 150 
of the LP, and at different positions along the villus-crypt axis (Figure 2A). A specific 151 
population expressing CD169 is found near the crypt base, close to the submucosa and 152 
these may have distinct functions and developmental requirements51,52. Substantial 153 
numbers of mφs are also found in the external muscularis layer of the intestine (Figure 1A). 154 
These are morphologically, phenotypically and transcriptionally distinct from those in the LP, 155 
selectively expressing a number of genes associated with tissue repair53. Being located close 156 
to neurons in submucosal ganglia, they also engage in two-way interactions with the enteric 157 
nervous system and respond to luminal bacteria via signals from nor-adrenergic nerves54,55. 158 
 159 
B) Lung Macrophages.  160 
The lung harbours at least two different mφ populations that occupy distinct 161 
anatomical niches (Figure 1B). The largest of these inhabits the alveolar space (alveolar 162 
macrophages - AMs), where they represent ~90-95% of leukocytes and reside in a precisely 163 
defined niche on the luminal side of the lung alveoli. In both mice and humans, AMs can be 164 
identified by their high auto-fluorescence and expression of CD64, as well as high levels of 165 
CD11c and CD169 (Table 1)4,56-58. However, important phenotypic differences exist between 166 
AMs in mice and men (Table 1). For instance, although SiglecF is a signature molecule for 167 
murine AMs4, its functional paralog, Siglec8, is absent from human AM58 (Table 1). AMs 168 
develop from foetal liver monocytes under the control of CSF2 (GM-CSF) in the first days of 169 
life, paralleling the development of the alveoli59 (Figure 1B) and then maintain themselves 170 
by in situ self-renewal 57. 171 
One of the principal homeostatic functions of AMs is regulating the levels of 172 
pulmonary surfactant, the proteolipid complex synthesised and secreted by the respiratory 173 
epithelium (Figure 1B). Indeed the transcriptional signature of AMs features several genes 174 
implicated in lipid metabolism4,60 and pulmonary alveolar proteinosis (PAP) develops due to 175 
excessive surfactant accumulation when AM development is defective, for instance in mice 176 
and humans in whom the CSF2-CSF2R axis has been disrupted8. There is continual bi-177 
directional crosstalk between AM and AEC, which is crucial for AM differentiation and 178 
functions, including lipid catabolism61 and cytokine production62. For instance, CSF2 179 
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produced by AEC induces the expression of PPARγ in AMs, which controls much of their 180 
unique phenotypic and functional identity. AMs also maintain the integrity of the alveolar 181 
space by removing senescent cells and inhaled particles, and by acting as a first line of 182 
defence against pathogens63. Like intestinal mφs, AMs respond poorly to activation by TLR 183 
ligands and other stimuli63,64, allowing them to scavenge and eliminate environmental 184 
antigens in a non-phlogistic manner. This hyporesponsive state is maintained by inhibitory 185 
receptors on AMs, including CD200R, IL10R and TGFβR which recognise their respective 186 
ligands on AECs64. Binding of epithelial-derived surfactant proteins, of which SP-A and SP-D 187 
are the most abundant, to receptors such as SIRPα can also modify phagocytosis, cytokine 188 
production and TLR responsiveness of AMs65. AMs are also critical in maintaining airway 189 
tolerance to innocuous antigens by supporting the differentiation of antigen-specific Treg66.  190 
AMs may also directly regulate the reactivity of AECs to their environment through the 191 
release of exosomes and microvesicles containing suppressor of cytokine signalling (SOCS) 192 
proteins67. Continual interaction with the AEC is also proposed to account for AMs 193 
remaining relatively sessile under both steady state conditions and after challenge with 194 
bacterial stimuli68.  195 
Mφs are also found in the lung parenchyma (interstitium) between the alveoli and 196 
capillary beds (Figure 1B). These interstitial macrophages (IMs) can be distinguished from 197 
AMs by their distinct surface phenotype4,56,58,69 (Table 1) and they have a unique 198 
transcriptional signature70. Similar to intestinal mφ, IMs are MHCII+ and express variable 199 
levels of CD11c4,58,69,71, which can lead to their misclassification as DCs. Because different 200 
investigators have used divergent criteria to define IMs, there is limited understanding of 201 
their role in lung homeostasis72-74. However a prominent feature of IMs is their constitutive 202 
production of the anti-inflammatory cytokine IL1073,74, which is reported to control the 203 
immunogenicity of lung DCs73. Furthermore, they produce growth factors such as PDGFβ 204 
that are known to regulate fibroblast proliferation75. Although the developmental origin of 205 
IMs remains controversial69,70,76,77, they have been shown to require replacement by 206 
monocytes, suggesting that different anatomical niches in the same tissue use distinct 207 
mechanisms to maintain their macrophage populations69,70,76. 208 
C) Skin macrophages.  209 
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The skin consists of two anatomically distinct regions, the dermis and the epidermis, 210 
each of which contains phenotypically, developmentally and functionally distinct mφ 211 
populations (Figure 2A).  212 
Langerhans cells (LCs) are found in the stratified squamous epithelium of the 213 
epidermis and express the langerin molecule (CD207; see Table 1) responsible for the 214 
formation the characteristic Birbeck granules found exclusively in LCs78. For many years, LCs 215 
were considered the archetypal non-lymphoid DCs, but it is increasingly clear that they 216 
display features of both mφs and DCs79  (Figure 3A). As well as fulfilling classical DC functions, 217 
such as migration to draining LNs and antigen presentation79, mouse LCs express high levels 218 
of the DC-specific transcription factor Zbtb4680 and lack expression of the macrophage 219 
markers CD64 and MerTK79. Despite this, they can be distinguished from cDC2s based on 220 
their expression of  CD24 and lack of expression of CD2681 (Table 1). Unlike DCs, LCs are 221 
derived from foetal liver monocytes7, can exist autonomously from blood monocytes 222 
through in situ self-renewal and express the mφ-restricted TF MafB80. However significant 223 
differences exist between murine and human LC (Table 1), with the latter sharing 224 
characteristics with murine cDC1s, including machinery for cross presentation of antigens82. 225 
Unlike most other tissue mφs, LCs rely on the alternative CSF1R ligand, IL34, for their 226 
development, which is produced constitutively by keratinocytes83,84. Keratinocyte-derived 227 
TGFβ is also indispensable for LC development and maintenance85 (Figure 2A).  228 
Given their ability to migrate to the draining LNs and act as APCs, LCs have been 229 
implicated in initiating immune responses. As discussed below, this can involve priming of 230 
effector T cells in the context of infection. However in steady state conditions, they may 231 
have an intrinsically tolerogenic role86, with increased contact hypersensitivity to haptens 232 
having been described in mice lacking LCs87.  Thus LCs may be similar to other DC-like APCs 233 
in being able to adapt flexibly to the needs of their environment. 234 
The mφ compartment of the underlying dermis is heterogeneous79 and they are 235 
phenotypically distinct from their epidermal neighbours in both mice and humans (Table 236 
1)88 (Figure 3A). Notably, mature dermal mφs in mice exhibit bimodal expression of MHCII 237 
and although the relationship between the MHCII+ and MHCII– subsets remains unclear, 238 
they display differences in transcriptome and turnover kinetics76,88. Dermal mφs develop 239 
initially from embryonic progenitors, but as in the intestine, these are displaced 240 
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progressively by BM-derived monocytes89. Adult dermal MHCII+ mφs then require 241 
continuous replenishment from circulating monocytes88 (Figure 2A), in a process influenced, 242 
in part, by the microbiota88. Apart from a clear role of CSF1R signalling90, to date, little is 243 
known regarding the factors involved in dermal mφ differentiation. Whether MHCII-defined 244 
subsets exist in human skin remains unclear, because HLA-DR expression is often used as 245 
the starting point for identifying MPs in human skin91,92. Although dermal mφs are poor 246 
APCs88, as in the intestine they may help maintain the dermal T cell compartment91, 247 
possibly through their constitutive production of IL1088 (Figure 2A). They have also been 248 
proposed to act as sentinels of invasion, expressing a number of genes associated with 249 
killing of microorganisms and displaying avid phagocytic ability88.  250 
 251 
D) Liver macrophages.  252 
Although not always thought of as a barrier tissue, the liver receives all blood 253 
draining the intestine via the portal vein and is thus continually exposed to products of both 254 
the diet and the microbiota. Kupffer cells (KCs) are the principal mφs of the liver, where 255 
they reside in the sinusoids, in a perfect position to monitor materials emanating from the 256 
intestine (Figure 2B). KCs develop during embryogenesis from yolk sac precursors and fetal 257 
liver monocytes, which then self-renew throughout life7. However, circulating monocytes 258 
have also been shown to contribute (albeit at low levels) to the KC pool during liver growth 259 
in the first few weeks of life93 and HSC-derived cells may also contribute to the KC pool with 260 
age94 (Figure 2B). As well as generic mφ markers, KCs express intermediate levels of CD11b 261 
and MHCII, distinguishing them from other CD11bhi myeloid cells in the liver93 (Table 1). In 262 
addition, murine KCs express high levels of the phagocytic receptor Tim493,95, the 263 
complement receptor VSIG4 (or CRIg)96,97 and uniquely among tissue mφs, the C-type lectin 264 
Clec4F23,93,98 (Table 1). Human hepatic mφs express CD68, CD64 and CD16399,100, but 265 
whether these markers are restricted to KCs, or are also present on other liver MP is unclear. 266 
Notably, although Clec4F is not conserved in humans, both VSIG4 and Tim4 are expressed 267 
by human KCs96 (Scott,  Guilliams Unpublished observations) (Table 1).   268 
KCs have been suggested to act as a firewall preventing systemic dissemination of 269 
microbes and their products from the intestine101,102 (Figure 2B). The liver has been 270 
particularly associated with the induction of tolerance to orally administered proteins103 271 
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and administration of antigen into the portal vein has been reported to induce systemic 272 
tolerance, while portal vein shunting abrogates oral tolerance104-107. Given their phagocytic 273 
capacity and their expression of MHCII, KCs have been suggested to be key to this process, 274 
both as APCs108-111 and by regulating the local immune environment via the production of 275 
immunosuppressive cytokines including IL10 and TGFβ112,113. The normally tolerogenic 276 
properties of KCs however, have been suggested to be overridden by stimuli such as TLR 277 
ligands, suggesting they could also play a role in active immunity against microbial 278 
infections114-116, however, whether this represents true KC plasticity or the presence of non-279 
KCs which respond to TLRs remains to be investigated.  280 
KCs also play important homeostatic roles in iron metabolism and recycling117, and 281 
they express a number of genes involved in these processes, including Cd163, Slc40a1, 282 
Hmox1, Hpx and Scd193 (Figure 2B). These properties are shared with splenic red pulp mφs, 283 
which are also exposed constantly to blood95,118. Stimulation of iron metabolism in KCs by 284 
IL6 and IL1 can contribute to control of infection via deprivation of iron from pathogens119. 285 
Indeed, patients with a deficiency in hepicidin, which induces the expression of a number of 286 
proteins involved in iron scavenging and sequestration in KCs, are more susceptible to 287 
infection with iron-dependent microbes120-122. The KC transcriptome is also enriched for 288 
genes involved in lipid metabolism93 and KCs have been implicated in the pathogenesis of 289 
diseases associated with excessive lipid consumption, including non-alcoholic fatty liver 290 
disease (NAFLD) and non-alcoholic steatohepatitis (NASH)123-125 (see below).     291 
  292 
3. Tissue macrophages under non-steady state conditions 293 
One of the most important gaps in our current knowledge of tissue-resident mφs is 294 
that the study of their behaviour under non-homeostatic conditions such as infection and 295 
inflammatory disease remains in its infancy (Box 1 and Figure 3). Below we review what is 296 
known about barrier tissue mφs under these circumstances, focusing on work that is 297 
compatible with the recent advances in understanding their phenotype and biology.  298 
 299 
A) Intestinal Macrophages 300 
Intestinal disorders such as IBD and infection are accompanied by intense 301 
infiltration with mφs and monocytes126. The success of anti-TNFα therapy in Crohn’s 302 
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disease highlights the practical relevance of understanding the underlying processes. In 303 
both humans and animals, the majority of the infiltrate in inflamed mucosa is made up of 304 
monocytes and immature mφs, while the numbers of mature mφs are usually normal, or 305 
even reduced compared with steady state intestine14,15,21,127. Furthermore, the relatively 306 
immature cells account for most of the pro-inflammatory mediators such IL1, IL6, TNFα, 307 
IL23, NO and ROI14-18,127,128. As well as causing tissue damage and/or targeting microbes 308 
directly, these mediators can also activate other effector cells of the innate and adaptive 309 
immune system, such as monocytes, neutrophils, Th17 cells and Th1 cells. Pro-310 
inflammatory monocytes/mφs also produce chemokines such as CCL2, CCL3, CCL4, CCL5, 311 
CCL8 and CCL11 which recruit eosinophils and neutrophils, as well as more 312 
monocytes51,129,130. As in steady state intestine, the enhanced recruitment of monocytes 313 
into inflamed intestine is driven mostly by CCR2126,131, although other chemokine-314 
receptors may also contribute, such as CCL3 and its receptor CCR1132.  315 
The monocytes that infiltrate the inflamed mucosa of humans and mice are 316 
phenotypically indistinguishable from those which replenish the mature mφ pool under 317 
steady state conditions. However their development appears to be arrested before they 318 
acquire significant anti-inflammatory properties such as production of IL10 or hypo-319 
responsiveness to stimulation14-16. The reasons for this block in differentiation are unclear, 320 
although one possibility could be that the monocytes recruited to the inflamed intestine 321 
are already intrinsically different. A process of this kind has been found in murine 322 
Toxoplasmosis, where IL12 released from the inflamed mucosa alters monocyte 323 
differentiation in the BM via the production of IFNγ133, but this has not yet been explored 324 
in other contexts.  325 
It is controversial whether the original fully mature mφs also contribute to intestinal 326 
inflammation (Box 1 and Figure 3). Although mature resident mφs do not become pro-327 
inflammatory during experimental colitis induced by chemicals or T cells14,16,18, this can 328 
occur under conditions when inflammation occurs in the absence of IL10 mediated control 329 
of mφ activity21,128. One population of resident mφs that may contribute directly to 330 
inflammation is that expressing CD169, which recruits monocyte neutrophils via production 331 
of CCL851,52.  Furthermore, muscularis mφs play important roles in postoperative paralytic 332 
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ileus by producing nitric oxide in response to local trauma, leading to activation of 333 
neighbouring neurons54. 334 
Mφs also play a role in the protective immunity that expels large extracellular 335 
microorganisms such as intestinal helminths134,135. During such Th2 responses, mφs produce 336 
arginase and RELMα135,136, together with chemokines that can recruit eosinophils and other 337 
effector cells130. This generates an environment detrimental to parasite survival, 338 
encouraging their expulsion. As in other forms of intestinal inflammation, newly recruited 339 
monocytes seem to be the most important source of activated, effector mφs in these Th2-340 
dependent immune responses135. However as IL4 dependent local proliferation and 341 
activation of pre-existing resident mφs has been described in parasite infection of the serous 342 
cavities137, similar processes might be feasible in the intestine. 343 
Mφs are important for tissue repair and restoration of homeostasis after inflammation in 344 
the intestine. This may involve their ability to drive epithelial stem cell renewal32,138, while 345 
IL1-mediated induction of IL22 from ILC3 helps restore epithelial barrier function and has 346 
anti-microbial effects131,139. Mφs may also protect against intestinal inflammation induced 347 
by the chemical DSS by suppressing production of the alarmin IL33140, while their ability to 348 
produce arginase during Th2 mediated immune responses is a crucial component of tissue 349 
repair after helminth infection141,142. As a result of these properties, depletion of mφ delays 350 
recovery from experimental colitis138,140,143. Whether these are functions of pre-existing 351 
resident mφ or of the monocytes recruited during the initial pathology is again unclear, 352 
although recent studies have shown that apparently pro-inflammatory monocytes recruited 353 
during murine Toxoplasmosis may protect against immunopathology by producing PGE2 354 
supressing neutrophil activation127. Both GM-CSF and VEGF-C produced during 355 
inflammation have been shown to induce reparative properties in intestinal mφs144. 356 
 357 
B) Lung Macrophages 358 
Given their positioning in the airway, it is unsurprising that AMs are key effector cells 359 
in the protective response against bacterial, viral and fungal infections. By virtue of their 360 
expression of a range of PRRs and high phagolysosomal capacity, AMs excel at engulfing and 361 
destroying extracellular bacteria such as Streptococcus pneumonia63. AMs also orchestrate 362 
the recruitment of neutrophils and effector monocytes to the lung through release of IL1β, 363 
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which induces CXCL8 production by the respiratory epithelium145. They are also potent 364 
producers of type 1 IFN in response to viral infections and orchestrate the recruitment of 365 
anti-viral monocytes146. AMs enhance viral clearance during influenza infection and there is 366 
increased lung pathology in systems in which AMs have been depleted64,147. Conversely, the 367 
activation threshold of AM may be heightened following severe viral infection, leaving 368 
individuals more susceptible to bacterial infections. This may involve changes in expression 369 
of inhibitory ligands by AEC 64. 370 
AMs have also been implicated in the development and progression of asthma, 371 
although it remains uncertain whether they play a pathogenic or protective role148. On one 372 
hand, depletion of AMs worsens allergen-induced airway inflammation149 and adoptive 373 
transfer of normal AMs can protect sensitised lungs from damage149. Moreover, AMs from 374 
asthmatic patients produce more IL10 than their counterparts from healthy lungs150. 375 
However, AMs from allergen-sensitised mice are more able to stimulate T cell responses 376 
and AMs from asthmatic patients express higher levels of costimulatory molecules such as 377 
CD80151, suggesting asthmatic AMs may be able to promote pathogenic Th2 responses, 378 
perhaps through their production of IL13147.  379 
  The role of IMs in lung inflammation or infection is poorly understood, although 380 
they have been shown to confer protection against allergic airway inflammation by 381 
producing IL10152. Whether this is a property of resident IMs or whether elicited monocyte-382 
derived macrophages can also do this is unclear. Similarly, whether IM-derived IL10 plays an 383 
important role in other models of disease remains to be determined. IM also release EGF 384 
which has been suggested to promote alveolar fluid clearance through promotion of 385 
epithelial sodium channels153.  386 
 Pulmonary mφs are important in driving the fibrogenesis, matrix remodelling and re-387 
epithelialisation of the alveolar wall that are all essential for the restoration of barrier 388 
integrity and efficient gas exchange following lung injury. AMs produce multiple growth 389 
factors that promote re-epithelialisation of the alveolar wall, including VEGF, PDGF, FGF, 390 
TGFβ154,155. TNFα from AMs also upregulates CSF2 production from AECs, stimulating AEC 391 
proliferation156,157 and supporting AM maintenance. Efferocytosis of apoptotic cells also 392 
promotes pro-reparative functions of AMs, including the production of PGE2, PAF and 393 
TGFβ158. Somewhat paradoxically, lung mφs have been implicated in the pathogenesis of 394 
interstitial lung diseases, such as idiopathic pulmonary fibrosis (IPF) in which there is 395 
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uncontrolled fibrogenesis. The relative roles of tissue-resident AMs, IMs and monocyte-396 
derived infiltrating mφs in this condition remain poorly understood8. For instance, although 397 
AMs can promote resolution of experimental bleomycin-induced fibrosis159, AMs from PF 398 
patients produce many pro-fibrotic mediators including TGFβ160 and CCL18161 and depletion 399 
of mφs (AMs or infiltrating mφs) reduces fibrogenesis in the same model162. However, this 400 
could be explained by recent work demonstrating that origin of AMs can influence their 401 
function. Experimental fibrosis disrupts the autonomous renewal of AMs, leading to the 402 
recruitment of BM-derived AMs that are more pro-fibrogenic than their resident 403 
counterparts163. How origin dictates function remains unclear, although one possibility is 404 
that resident and BM-derived AMs might occupy different micro-anatomical niches and that 405 
this controls their function. As discussed in Box 1, the roles of developmentally-distinct 406 
macrophages in other settings has not been examined, including during pulmonary 407 
emphysema where mφs may also contribute to loss of alveolar architecture through their 408 
enhanced production of matrix metalloproteinases MMP1 and MMP1264. 409 
 410 
C) Skin Macrophages 411 
Langerhans cells have been shown to induce active Th17 responses during cutaneous 412 
Candida albicans infection164 and can participate in effector CD8+ T cell priming in LNs 413 
during Herpes simplex virus (HSV) infection, either by presenting antigen directly to T cells 414 
or after transfer to cDC1s165,166. Recently, it was shown that CD1a on LCs can amplify Th17-415 
driven models of dermatitis and psoriasis167. Importantly, blocking CD1a through 416 
administration of anti-CD1a antibodies significantly reduced skin inflammation167, providing 417 
a putative therapeutic option for patients with Th17 mediated skin diseases. Although 418 
phenotypically-distinct (MHCIIhi) monocyte-derived LCs have been shown to accumulate 419 
during models of injury/inflammation168, it remains unclear if these or pre-existing resident 420 
cells are responsible for the pro-inflammatory functions of LC under these conditions.  421 
 422 
Little is known regarding the roles of dermal mφs under non-homeostatic conditions. 423 
Dermal monocyte-derived cells have been shown to accumulate in and drive development 424 
of psoriasis-like inflammation79,168, but not in other forms of inflammation such as contact 425 
allergen induced dermatitis88. Dermal mφs may play a role in the first line of defence against 426 
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pathogens, having been shown to induce neutrophil extravasation in responses to local 427 
infection with Staphylococcus aureus169. Dermal mφs are also essential for wound healing 428 
and restoration of tissue integrity following mechanical skin injury. Again the relative 429 
contribution of fully mature resident mφs versus elicited monocyte-derived cells is unclear, 430 
but macrophages are essential for neovascularisation, collagen fibril assembly and scab 431 
formation, in a process dependent on IL4R signalling170. IL4/IL13 polarised dermal 432 
macrophages are also implicated in driving tissue fibrosis through their production of 433 
RELMα which promotes pro-fibrotic collagen crosslinking by dermal fibroblasts170. A 434 
population of flt3L-dependent, migratory moDCs has been reported in the dermis under 435 
both homeostatic and inflammatory conditions, but the exact nature of these cells remains 436 
unclear, as does their relationship to dermal mφs (Box 1).  437 
 438 
D) Liver Macrophages 439 
KCs have been implicated in several acute and chronic hepatic pathologies, including 440 
ischemia/reperfusion (I/R-) injury, acetaminophen hepatoxicity (AILI), liver fibrosis, alcoholic 441 
liver disease (ALD), viral hepatitis, non-alcoholic steatohepatitis (NASH), non-alcoholic fatty 442 
liver disease (NAFLD) and hepatocellular carcinoma (HCC). However contradictory findings 443 
have been reported on the exact roles of KCs in these conditions171. In I/R-injury, for 444 
example, KCs have been attributed both pathogenic and protective roles, driven by TNFα, 445 
IL1β and reactive oxygen species (ROS) and IL10 respectively172-174. Analogous findings have 446 
been reported in viral hepatitis, where KCs have been suggested to produce both anti-viral 447 
mediators and to suppress protective immunity175. These contrasting conclusions may 448 
reflect the fact that previous studies did not distinguish between bona fide KCs and 449 
infiltrating monocytes/mφs, or used depletion strategies that targeted all myeloid cells in 450 
the liver.  451 
More recent studies have attempted to explore the relative roles of these cell types 452 
in inflammatory liver pathology. Notably, KCs maintain their distinct transcriptional profile 453 
following acetaminophen-induced liver injury, remaining largely identical to their steady 454 
state counterparts176. However, as the damage following paracetamol overdose is restricted 455 
anatomically, it will be interesting to determine if specific KCs located in the damaged areas 456 
do respond to the injury and if perhaps this has been overlooked using bulk transcriptomic 457 
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techniques. Interestingly, the infiltrating monocytes/mφs are thought to both aggravate the 458 
early stages of this disorder177 and to be necessary for the subsequent resolution of the 459 
inflammation176. Notably, recruited monocyte-derived mφs do not appear to develop into 460 
bona fide KCs under these conditions rather generating short-lived macrophages 176 (Scott, 461 
Guilliams unpublished observations). In contrast, monocyte-derived KCs can be found during 462 
Listeria monocytogenes infection178. In this infection, early uptake of bacteria triggers KC 463 
death by necroptosis and bacteria are subsequently eliminated by recruited monocyte 464 
derived macrophages which later develop into bona fide KCs178. However, it remains to be 465 
seen if KC death following bacterial uptake is required for the effective clearance of the 466 
bacteria and return to liver homeostasis, furthermore, the impact of mφ origin on these 467 
functions requires further study (Box 1). Thus there is still much to learn regarding the 468 
specific functions of KCs and recruited monocyte-derived mφs in the liver under non-469 
homeostatic conditions. The use of the newly defined markers capable of discriminating 470 
between KCs and other recruited monocyte-derived mφs, as well as investigating differences 471 
in micro-anatomical location, will be critical to truly assess mφ function during these 472 
pathologies.  473 
 474 
4. Summary and Future Perspectives  475 
Many of the central dogmas about the origin and function of mφs in barrier tissues 476 
have been completely revised in recent years, with an increasing awareness of their 477 
heterogeneity and diversity of physiological roles. Rather than depending on their origin, 478 
the properties of mφs are highly tissue specific and appear to be imprinted locally, ensuring 479 
precise adaptation to the demands of their environment. These properties offer clear 480 
possibilities for targeted therapeutic intervention, with the aim of restoring homeostasis. 481 
However for this to be achieved, the factors driving the specification of different tissue-482 
resident mφ populations under homeostatic conditions would be crucial to identify. 483 
Determining the relative roles played by resident and infiltrating mφs during infection or 484 
inflammation could create further options for preventing their recruitment or activation. 485 
 486 
 487 
  488 
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Box 1: Macrophage behaviour under non-homeostatic conditions 489 
Disruption of local homeostasis due to inflammation or infection results in a 490 
drastically altered local environment, with damage to tissue cells and induction of an innate 491 
immune response. These lead to increased production of inflammatory cytokines and 492 
chemokines, together with recruitment of inflammatory cells including neutrophils and 493 
monocytes, the latter of which can differentiate into mφs. An important unanswered 494 
question concerns the relative roles of newly recruited and pre-existing mφs in inflammation 495 
(Figure 3). Although it is clear that recruited monocytes are sufficiently plastic to respond 496 
appropriately to the changing environment, there is less evidence that the tissue-resident 497 
mφs can modify their homeostatic functions to become pro-inflammatory under such 498 
circumstances. Indeed the findings that the tissue conditioned properties of resident mφs 499 
are determined at the level of the epigenome23 would suggest it may be difficult for these 500 
cells to change in response to new triggers, although this too is likely to be tissue-specific. 501 
Importantly there is evidence that pre-existing tissue-resident and newly recruited 502 
inflammatory mφs can respond differently to stimuli, at least in the peritoneal cavity, lung 503 
and liver163,178,179. This has clear implications for designing mφ-targeted therapy in 504 
inflammation.  505 
In many tissues, inflammation is associated with a reduction in the resident mφ 506 
population, often referred to as the ‘mφ disappearance reaction’. The mechanisms 507 
responsible are likely to be specific to each inflammatory insult, but could include cell death, 508 
increased adherence to tissue stroma, or emigration from the tissue. A controversial topic is 509 
whether monocytes and/or mφs can migrate from inflamed tissues to draining LNs and 510 
present antigen to T cells, thus behaving as “monocyte-derived DCs” (mo-DCs). This is a 511 
longstanding concept in myeloid cell biology and although mφs do not migrate to LNs under 512 
steady state conditions, during inflammation in tissues such as the gut and lung, some 513 
monocytes may upregulate CCR7, migrate to draining LNs and present antigen to naïve T 514 
cells180. As these cells express MafB, but not Zbtb46, they appear to be mφs rather than part 515 
of the genuine DC lineage80. Although this is likely a relatively rare process, it would clearly 516 
be an effective way of expanding the range of APC capable of driving effector T cell 517 
responses in protective immunity and underlines the plasticity of recruited monocytes. 518 
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During recovery from inflammation or infection, the mφ population typically returns 519 
to steady state levels and can also contribute to the restoration of tissue homeostasis. Again 520 
it is unclear if these processes reflect differentiation of the recruited inflammatory 521 
monocytes/mφs into mφs with repair functions or via a second wave of monocyte 522 
recruitment and mφ differentiation. Similarly, it is not known if the replenishment of mφ 523 
numbers occurs through proliferation of the remaining resident mφ population or additional 524 
recruitment of monocytes, or a combination of these processes (Figure 3).  525 
 526 
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Figure Legends 958 
 959 
Figure 1: Barrier tissue macrophage function under homeostatic conditions. A) Resident 960 
mφs in the lamina propria of the intestine express high levels of many receptors for 961 
apoptotic cells, ideal for clearing the large amounts of cell death found in this rapidly 962 
turning over tissue14,18-22. Production of trophic factors for epithelial stem cells and tissue 963 
remodelling metalloproteinases helps maintain barrier integrity20,28-34. Being actively 964 
phagocytic and bactericidal, LP mφs are crucial in shaping host-microbiota symbiosis and 965 
may send processes across the epithelial barrier to sample contents of the lumen. They 966 
acquire many antigens avidly and pass these on to neighbouring migratory DCs for 967 
presentation to T cells in the draining mesenteric lymph node46,47. Intestinal mφs in adults 968 
are replenished continuously by circulating Ly6Chi monocytes14,16,25, which differentiate 969 
locally under the control of environmental signals such as TGFβ20, a process associated with 970 
the expression of the TF RUNX3 and KLF10 (Ref. 23). The inability of mature intestinal mφs 971 
to respond to pattern recognition receptor triggering is controlled by IL10 (Refs 21, 41-43). 972 
Constitutive production of IL10 and other cytokines sustains the survival of other immune 973 
cells in the vicinity, including FoxP3+ Treg35,44 and ILC3 (Ref. 38), while release of chemokines 974 
such as CCL2 allows the mφs to recruit their own monocyte precursors and other 975 
leukocytes17,20. Mφs in the muscularis mucosa are involved in two-way interactions with 976 
sympathetic neurons of the enteric nervous system and express high levels of the β2 977 
adrenergic receptor (β2AR)53,54. Signalling through the β2AR drives anti-inflammatory and 978 
pro-repair properties in the mφs, including the production of IL10 and RELMα, while bone 979 
morphogenic protein 2 (BMP2) produced by muscularis mφs in response to microbial signals 980 
regulates neuronal function53,54. B) Alveolar mφs (AMs) in the lung are crucial for 981 
maintaining patency of the alveolar space, where they regulate surfactant levels and 982 
phagocytose inhaled microbes and other particulate materials59,61. They communicate 983 
intimately with alveolar epithelial cells, removing dead cells and controlling their renewal. 984 
AMs maintain an anti-inflammatory environment via expression of inhibitory cytokines and 985 
receptors that regulate T cell responses and local innate immune reactions. AMs are derived 986 
from foetal liver monocytes during the neonatal period that subsequently self-renew for 987 
much of adult life57,59. AM differentiation is driven by CSF2 acting by inducing the expression 988 
of the TF PPARγ59,61,62, whose ligands may include lipid-rich materials such as surfactant 989 
present in the alveolar space. Other TFs involved in AM development include Bach2 and 990 
C/EBPβ181,182. The specific functions of steady state interstitial mφs (IMs) are not yet known, 991 
but may include second line defence against microbes, promotion of anti-inflammatory T 992 
cell responses and shaping local DC functions73. The origin(s) of IMs remain 993 
controversial69,70,76,77 and the signals and TFs involved in their specification are yet to be 994 
determined.  995 
 996 
Figure 2: Barrier tissue macrophage function under homeostatic conditions. A) Langerhans 997 
cells (LCs) in the epidermis have transcriptional and functional properties of both mφs and 998 
DCs79,80. They are highly phagocytic and proficient at acquiring antigen from the 999 
environment, but can also transport this to draining lymph nodes and present it to T cells, 1000 
helping to maintain tolerance in the steady state. LCs are derived from yolk sac precursors 1001 
and foetal liver monocytes77, 89, and their differentiation is regulated by TGFβ85 and the 1002 
CSF1R ligand IL34 (Refs. 83), together with the TFs AhR and RUNX3. Dermal mφs appear to 1003 
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contain descendants of both embryonic precursors and Ly6Chi monocytes, with the latter 1004 
being dominant in adult life88, but the factors involved in their differentiation and their 1005 
tissue-specific roles remain to be determined. B) Kupffer cells are located at the intersection 1006 
of the enteric and peripheral circulatory systems. Thus they are in an ideal position to act as 1007 
a firewall against microbes and other factors arriving from the intestine in the portal 1008 
veins101,102, and they have been implicated in maintaining tolerance to these materials, 1009 
either directly by presenting antigen to T cells, or by maintaining an immunosuppressive 1010 
local environment103-114. Kupffer cells play a crucial role in recycling of iron from senescent 1011 
red blood cells and are also involved in metabolism of lipids and transport of the resulting 1012 
products into bile95,117. As they are closely associated with other parenchymal cells such as 1013 
hepatocytes and liver sinusoidal endothelial cells (LSECs), it is likely that KCs may be 1014 
important in the homeostasis of these cell types8. Kupffer cells develop from foetal liver 1015 
monocyte precursors89 and this is driven by heme derived from the recycling of effete red 1016 
blood cells95, together with the ID3 TF183. Additional, as yet unidentified, signals are likely to 1017 
be involved in the specification of all these tissue-resident mφ populations.  1018 
 1019 
 1020 
Figure 3: Macrophages in barrier tissues under non-homeostatic conditions. Disruption of 1021 
homeostasis by infection or inflammation leads to the recruitment of Ly6Chi monocytes and 1022 
other inflammatory leukocytes such as neutrophils and eosinophils. The Ly6Chi monocytes 1023 
generate inflammatory mφs and together, these are the main sources of mediators such as 1024 
TNFα, IL1 and IL6 (Refs. 17, 176). It appears that most of these monocytes do not 1025 
differentiate into fully mature mφs as they would under homeostatic conditions, due to an 1026 
arrest in this process and so these inflammatory cells may be short-lived14. An additional 1027 
source of pro-inflammatory mφs during inflammation may be monocytes whose properties 1028 
have already been programmed differently before leaving the bone marrow in response to 1029 
signals generated in the inflamed tissue133. The role of the original tissue resident mφ 1030 
population in inflammation remains unclear. They may act as early sentinels of tissue 1031 
damage and recruit monocytes and granulocytes via production of CCL2, CCL8, CCL11, 1032 
CXCL2 and other chemokines. However in many tissues, the numbers of resident mφs are 1033 
often reduced during the immediate response to tissue injury, the so-called macrophage 1034 
disappearance reaction. Whether the remaining cells can alter their normal anti-1035 
inflammatory properties to contribute to pathology and protective immunity is not fully 1036 
understood and may depend on the circumstances or tissue involved14,17,137,146,163, 168,176. 1037 
Many questions also remain unanswered regarding the fate of the monocytes and mφs 1038 
upon return to homeostasis. For example, do activated tissue-resident mφs return to steady 1039 
state? Do the recruited monocyte-derived mφs die, persist in the tissue as monocyte-1040 
derived mφs or become monocyte-derived tissue resident mφs? Finally, it is unclear if 1041 
additional monocytes are recruited to help replenish the resident mφ niche and how each of 1042 
these cells might contribute to the tissue repair process. 1043 
 1044 
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Table 1: Surface Markers of Major Macrophage Subsets in Barrier Tissues. 1046 
 1047 
Tissue Macrophage 
Subset Surface Phenotype 
Mouse Human References
Intestine Lamina Propria 
CD64+ SIRPα+ 
MHCII+ CD163+ 
CD68+ 
F4/80+ 
MerTK+ CD11b+ 
CX3CR1hi 
CD11c+/– 
CD206+ 
Tim4+/– αvβ5+ 
CD36+ 
CD64+ SIRPα+ 
HLA-DR+ CD163+ 
  
  
14,16-20,22,81 
Lung 
Alveolar 
CD64+ F4/80+ 
MerTK+ SIRPα+ 
CD11b– MHCII– 
CX3CR1– CD11chi 
SiglecF+ CD169+ 
CD206+ CD163– 
CD64+ CD11b+ 
HLA-DR+ CD163+ 
Siglec8– CD169+ 
 
56,57,58,81 
Interstitial 
CD64+ CD14+
MHCII+ SIRPα+ 
F4/80+ 
MerTK+ CD11b+ 
CX3CR1hi 
CD11c+/– 
CD64+ CD14+ 
HLA-DR+ SIRPα+ 
CD36+ 
CD169–  
CD11c+/–   
56,58,69-71,81 
Skin 
Langerhans Cells 
CD64– F4/80+ 
MerTK– CD11c+ 
CD11b+ EpCam+ 
MHCII+ SIRPα+ 
CD207+CD24+  
CD26- 
CD1a+ CD14+ 
HLA-DR+ CD207+ 
  
78,79,81,82 
Dermal  
CD64+ F4/80+ 
MerTK+ EpCam– 
CD207– MHCII+/– 
CD11c+/– 
CD64+ CD1a– CD14+ 
FXIIIa+ CD163+ 
81,88,91 
Liver Kupffer Cells 
CD64+ F4/80+ 
MerTK+ MHCII+ 
CD11bint CD11clo 
Clec4F+ VSIG4+ 
Tim4+ SIRPα+ 
CX3CR1- 
CD64+  
CD163+ 
CD68+ VSIG4+ 
Tim4+ 
23,81,93,95-100,176 
 1048 
 1049 
 1050 
Mature M
CD64+ F4/80+
CD11b+ MHCIIhi
CX3CR1hi
CD169+ M
CX3CR1hi
CD11b+ CD64+
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